Biomedical Engineering Reference
In-Depth Information
in the blood for heart disease. The landmark FHS is launching a major initiative
to discover risk factors and biomarkers that could lead to new blood tests to
identify individuals at high risk of heart disease and stroke. It is funded by
NHLBI and conducted in collaboration with Boston University School of
Medicine and School of Public Health. A public-private partnership has been
established to enable researchers to apply cutting-edge technology to stored
blood samples from thousands of FHS participants. An important component of
the biomarker research will be conducted under a 5-year CRADA with BG
Medicine, which has developed patented technology to detect and validate subtle
biological changes at the molecular level. In 2010, Sigma-Aldrich joined this
project to discover biomarkers for atherosclerosis CVD in plasma samples.
Sigma will develop antibody reagents for each identified target biomarker and
incorporate the reagents into a multiplexed, high-throughput platform to mea-
sure proteins of interest.
Researchers from participating institutions will study about 1,000 blood bio-
markers. Frozen blood samples, imaging studies, and other medical test results
gathered over the years from more than 7,000 FHS participants of diverse ages will
be analyzed to identify which blood biomarkers are associated with heart disease,
metabolic syndrome, and related risk factors. Researchers will use only materials
from participants who have consented to sharing their specimens and data with
commercial sector scientists, and all shared information will be de-identified to
protect participants' privacy.
References
Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease.
J Physiol 2005;563:23-60.
Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and
amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP
Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol
2006;47:91-7.
Apple FS, Ler R, Chung AY, et al. Point-of-Care i-STAT Cardiac Troponin I for Assessment
of Patients with Symptoms Suggestive of Acute Coronary Syndrome. Clin Chem 2006;52:
322-5.
Arab S, Gramolini AO, Ping P, et al. Cardiovascular Proteomics: Tools to Develop Novel
Biomarkers and Potential Applications. J Am Coll Cardiol 2006;48:1733-1741.
Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP
modulates cardiac repolarization. Nat Genetics 2006;38:644-51.
Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-
binding protein: diagnostic assays and clinical applications. Clin Chem 2006;52:19-29.
Baggish AL, Siebert U, Lainchbury JG, et al. A validated clinical and biochemical score for the
diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency
Department (PRIDE) Acute Heart Failure Score. Am Heart J 2006;151:48-54.
Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Journal of Internal Medicine 2006;259:447-454.
Beishuizen A, Hartemink KJ, Vermes I, Groeneveld AJ. Circulating cardiovascular markers and
mediators in acute illness: an update. Clin Chim Acta 2005;354:21-34.
Search WWH ::
Custom Search